A detailed history of Avantax Planning Partners, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Avantax Planning Partners, Inc. holds 854 shares of VRTX stock, worth $375,435. This represents 0.01% of its overall portfolio holdings.

Number of Shares
854
Holding current value
$375,435
% of portfolio
0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$460.0 - $505.78 $392,840 - $431,936
854 New
854 $397,000
Q2 2018

Aug 13, 2018

SELL
$145.72 - $169.96 $10,929 - $12,747
-75 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$151.6 - $177.13 $11,370 - $13,284
75 New
75 $12,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $113B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Avantax Planning Partners, Inc. Portfolio

Follow Avantax Planning Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Planning Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Planning Partners, Inc. with notifications on news.